Literature DB >> 3009620

Demonstration of NK cell-mediated lysis of varicella-zoster virus (VZV)-infected cells: characterization of the effector cells.

A B Tilden, R Cauda, C E Grossi, C M Balch, A D Lakeman, R J Whitley.   

Abstract

Infection with varicella-zoster virus (VZV) rendered RAJI cells more susceptible to lysis by non-adherent blood lymphocytes. At an effector to target ratio of 80:1 the mean percentage of 51Cr release of VZV-infected RAJI cells was 41 +/- 12%, whereas that of uninfected RAJI cells was 15 +/- 6%. The increased susceptibility to lysis was associated with increased effector to target conjugate formation in immunofluorescence binding assays. The effector cells cytotoxic for VZV-infected RAJI cells were predominantly Leu-11a+ Leu-4- granular lymphocytes as demonstrated by fluorescence-activated cell sorting. The effector cell active against VZV-infected RAJI cells appeared similar to those active against herpes simplex virus (HSV)-infected cells, because in cold target competition experiments the lysis of 51Cr-labeled VZV-infected RAJI cells was efficiently inhibited by either unlabeled VZV-infected RAJI cells (mean 71% inhibition, 2:1 ratio unlabeled to labeled target) or HSV-infected RAJI cells (mean 69% inhibition) but not by uninfected RAJI cells (mean 10% inhibition). In contrast, competition experiments revealed donor heterogeneity in the overlap between effector cells for VZV- or HSV-infected RAJI vs K-562 cells.

Entities:  

Mesh:

Year:  1986        PMID: 3009620

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection.

Authors:  Tessa M Campbell; Brian P McSharry; Megan Steain; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

Review 2.  Vaccination for quality of life: herpes-zoster vaccines.

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Aging Clin Exp Res       Date:  2019-10-23       Impact factor: 3.636

3.  Inhibition of varicella-zoster virus in vitro by human peripheral blood mononuclear cells.

Authors:  G P Rabalais; F E Berkowitz; A R Hayward; M J Levin
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

4.  In vitro enhancement of natural killer cell activity against herpesvirus-infected targets in patients with acute lymphocytic leukemia.

Authors:  J R McKolanis; A H Ragab; D S Schmid
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

5.  Heterogeneity amongst natural killer cells revealed by limiting dilution culture; selectivity against virus-infected and tumour cell targets.

Authors:  P D Mason; J G Sissons; L K Borysiewicz
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

6.  Human herpesviridae methods of natural killer cell evasion.

Authors:  Carl I Odom; David C Gaston; James M Markert; Kevin A Cassady
Journal:  Adv Virol       Date:  2012-07-08

7.  Safety and Varicella Outcomes in In Utero-Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program.

Authors:  Jennifer M Duchon; Myron J Levin; Anne A Gershon
Journal:  J Pediatric Infect Dis Soc       Date:  2020-09-17       Impact factor: 3.164

Review 8.  Predictors of shingles reports at diagnosis of common variable immunodeficiency and selective immunoglobulin G subclass deficiency in 212 Alabama adults.

Authors:  James C Barton; J Clayborn Barton; Luigi F Bertoli
Journal:  Infect Dis Rep       Date:  2012-07-19

Review 9.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.